A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer.

Trial Profile

A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs Gemcitabine (Primary) ; Paclitaxel (Primary) ; Hydroxychloroquine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 15 Jun 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top